1
|
Wang S, Lei K, Lai HT, Liu T, Du L, Wu SY, Ye X, Chiang CM, Li M. Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells. ACS Pharmacol Transl Sci 2024; 7:1178-1190. [PMID: 38633583 PMCID: PMC11019737 DOI: 10.1021/acsptsci.4c00057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2024] [Revised: 02/28/2024] [Accepted: 03/01/2024] [Indexed: 04/19/2024]
Abstract
A promising alternative for cancer treatment involves targeted inhibition of the epigenetic regulator bromodomain-containing protein 4 (BRD4); however, available BRD4 inhibitors are constrained by their potency, oral bioavailability, and cytotoxicity. Herein, to overcome the drawback of the translational BRD4 inhibitors, we describe a novel BRD4-p53 inhibitor, SDU-071, which suppresses BRD4 interaction with the p53 tumor suppressor and its biological activity in MDA-MB-231 triple-negative breast cancer (TNBC) cells in vitro and in vivo. This novel small-molecule BRD4-p53 inhibitor suppresses cell proliferation, migration, and invasion by downregulating the expression of BRD4-targeted genes, such as c-Myc and Mucin 5AC, and inducing cell cycle arrest and apoptosis, as demonstrated in cultured MDA-MB-231 TNBC cells. Its antitumor activity is illustrated in an orthotopic mouse xenograft mammary tumor model. Overall, our results show that SDU-071 is a viable option for potentially treating TNBC as a new BRD4-p53 inhibitor.
Collapse
Affiliation(s)
- Shumei Wang
- Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE),
School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
| | - Kang Lei
- Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE),
School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
- School
of Pharmaceutical Sciences, Liaocheng University, Liaocheng, Shandong 252059, China
| | - Hsien-Tsung Lai
- Simmons
Comprehensive Cancer Center, University
of Texas Southwestern Medical Center, Dallas, Texas 75390, United States
| | - Tingting Liu
- Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE),
School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
| | - Lupei Du
- Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE),
School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
| | - Shwu-Yuan Wu
- Simmons
Comprehensive Cancer Center, University
of Texas Southwestern Medical Center, Dallas, Texas 75390, United States
- Department
of Biochemistry, University of Texas Southwestern
Medical Center, Dallas, Texas 75390, United States
| | - Xiaohan Ye
- Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE),
School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
| | - Cheng-Ming Chiang
- Simmons
Comprehensive Cancer Center, University
of Texas Southwestern Medical Center, Dallas, Texas 75390, United States
- Department
of Biochemistry, University of Texas Southwestern
Medical Center, Dallas, Texas 75390, United States
- Department
of Pharmacology, University of Texas Southwestern
Medical Center, Dallas, Texas 75390, United States
| | - Minyong Li
- Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE),
School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China
| |
Collapse
|